Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification is a research paper published in Journal of Clinical Oncology (2022). On theSindex it has a DataRank of 2.2. It has been cited 97 times, with 90 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.688
From this paper's citation signal
Citation Network Contribution
1.6
From 64 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 90 citers.
NCI NIH HHS
Grant: R01 CA223772
NCI NIH HHS
Grant: UM1 CA186717
NCI NIH HHS
Grant: UM1 CA186691
NCI NIH HHS
Grant: R01 CA255960
NCI NIH HHS
Grant: UM1 CA186688
NCI NIH HHS
Grant: P30 CA016672
NCI NIH HHS
Grant: P50 CA098258
Fields of Study
MeSH Terms